Episodic Cerebellar Ataxia Responding to Pyridostigmine

Why Pyridostigmine Response Matters

• EA1 (KCNA1 mutation, potassium channel): carbamazepine, some antiepileptics
• EA2 (CACNA1A mutation, P/Q-type calcium channel): acetazolamide, 4-aminopyridine (4-AP), dalfampridine

Key Diagnostic Entities

1. Congenital Myasthenic Syndrome (CMS) with Cerebellar/Ataxia Features

• GFPT1-CMS (glutamine-fructose-6-phosphate transaminase 1): limb-girdle weakness + tubular aggregates on biopsy; pyridostigmine is a mainstay
• DOK7-CMS (downstream of kinase 7): limb-girdle pattern, may have cerebellar features; pyridostigmine has limited benefit here
• CHAT-CMS (choline acetyltransferase): episodic apnea + weakness; pyridostigmine helpful
• COLQ-CMS (collagen Q): AChE deficiency at NMJ; pyridostigmine is contraindicated
• Slow-channel CMS (SCCMS, gain-of-function AChR mutations): pyridostigmine generally worsens - avoid
• Fast-channel CMS and AChR deficiency CMS: pyridostigmine is beneficial

2. Lambert-Eaton Myasthenic Syndrome (LEMS) with Cerebellar Involvement

• LEMS is caused by anti-P/Q-type VGCC (Cav2.1) antibodies - the same channel encoded by CACNA1A
• The anti-VGCC antibody attacks presynaptic calcium channels at the NMJ, impairing ACh vesicle release
• The same antibody can directly impair Purkinje cell function, causing cerebellar ataxia (paraneoplastic or non-paraneoplastic)
• Pyridostigmine provides modest symptomatic benefit in LEMS by increasing synaptic ACh at NMJ
• LEMS-associated cerebellar degeneration can be episodic early on, before becoming progressive
• This is supported by literature showing anti-VGCC antibodies causing cerebellar ataxia responsive to immunotherapy + symptomatic agents (PMID: 24215945)

3. EA2 (CACNA1A) with NMJ Overlap - Rare/Exceptional

• One case of pyridostigmine-responsive EA was noted in a CACNA1A cohort (100% response rate in that single case) in the 2026 Frontiers Neurology diagnostic algorithm paper
• The P/Q-type calcium channel (Cav2.1) encoded by CACNA1A is also present at presynaptic NMJ terminals, meaning CACNA1A loss-of-function mutations could theoretically impair both cerebellar Purkinje cell firing AND NMJ transmission
• This provides a plausible mechanistic rationale for why some EA2 patients might benefit from pyridostigmine (enhancing NMJ ACh availability to compensate for reduced presynaptic Ca2+ influx)

4. Secondary/Metabolic Episodic Ataxia

Mechanistic Framework

Clinical Approach When Pyridostigmine Response is Observed

1. Repetitive nerve stimulation (RNS) - look for decremental (MG/CMS) or incremental (LEMS) response
2. Single-fiber EMG (SFEMG) - most sensitive for NMJ transmission defect
3. Serum antibodies: anti-AChR, anti-MuSK, anti-VGCC (P/Q type), anti-CASPR2
4. Genetic panel: CMS gene panel (CHAT, RAPSN, COLQ, DOK7, AGRN, GFPT1, SLC5A7, etc.)
5. CT thorax/abdomen: exclude occult malignancy (LEMS is paraneoplastic in ~50-60% cases, mostly SCLC)
6. Cerebellar MRI: cerebellar atrophy suggests progressive/neurodegenerative component
7. Nerve conduction studies: LEMS shows low CMAP amplitude at rest, increments with high-frequency stimulation

Summary

1. A NMJ transmission disorder with cerebellar manifestations - CMS (presynaptic or postsynaptic subtypes with AChR deficiency) or LEMS
2. Rare EA2 (CACNA1A) where the same P/Q calcium channel defect affects both cerebellar and NMJ function

Note: Standard episodic ataxia types (EA1, EA2) do not routinely respond to pyridostigmine - the response to this agent is a red flag for an underlying NMJ disorder or a CACNA1A-related condition with NMJ co-involvement.

Age 55 + Episodic Cerebellar Ataxia + Pyridostigmine Response: Refined Analysis

Top Diagnosis: Lambert-Eaton Myasthenic Syndrome (LEMS) with Cerebellar Involvement

Why LEMS fits perfectly:

Clinical triad to look for alongside ataxia:

1. Proximal muscle weakness (especially lower limbs, hip girdle - difficulty rising from chair)
2. Hyporeflexia/areflexia that improves after brief exercise (post-exercise facilitation - pathognomonic)
3. Autonomic dysfunction - dry mouth, constipation, impotence, orthostatic hypotension

Mechanism of Pyridostigmine in this Context

Anti-VGCC Ab → ↓ Ca²+ influx at presynaptic terminal
              → ↓ ACh vesicle fusion & release
              → NMJ transmission failure

Pyridostigmine → inhibits AChE → ↑ synaptic ACh lifetime
              → partially compensates for reduced release
              → improves NMJ transmission symptoms

Cerebellar component:
Anti-VGCC Ab → also attacks Cav2.1 on Purkinje cells
              → ↓ inhibitory output from cerebellum
              → episodic ataxia (early) → progressive cerebellar degeneration (late)

Urgent Workup Required

• Anti-P/Q type VGCC antibodies (diagnostic for LEMS)
• Anti-SOX1 antibodies (highly specific for paraneoplastic LEMS with SCLC)
• Anti-Hu, anti-Yo, anti-Ri, anti-CV2/CRMP5 (broader paraneoplastic panel)
• Anti-AChR, anti-MuSK (exclude co-existing MG)

• Repetitive nerve stimulation (RNS): look for incremental response (>100% CMAP amplitude increase at 50Hz or after 10 sec maximal voluntary contraction) - this is the hallmark of LEMS
• SFEMG: increased jitter

• CT chest/abdomen/pelvis - screen for SCLC (lung) and other malignancies
• PET-CT if CT negative (higher sensitivity for occult tumors)
• MRI brain/cerebellum - cerebellar atrophy, T2 signal changes

Differential at Age 55 (Ranked by Probability)

Key Clinical Pearl

1. Check anti-VGCC antibodies and full paraneoplastic panel
2. Electrophysiology (RNS, SFEMG)
3. CT chest (SCLC screen) - if negative → PET-CT
4. If LEMS confirmed: start amifampridine (3,4-DAP) as first-line symptomatic treatment (pyridostigmine can be added as adjunct), plus immunosuppression (prednisolone ± azathioprine)
5. If malignancy found: oncology referral - treating the tumor often improves neurological symptoms